ABCELLERA BIOLOGICS INC

AbCellera Biologics posts a Q2 earnings miss but secures $110M in upfront cash for its ABCL635 drug; investors watch upcoming Phase II results and partnership deals for a potential turnaround.

AbCellera Biologics’ stock surges near its 52‑week high as investor confidence in next‑gen antibody pipelines grows, amid upcoming insider trading restrictions.

AbCellera Biologics drives antibody discovery with cutting‑edge genomics, microfluidics & AI, boosting investor confidence and setting the stage for key 2026 data releases.

AbCellera Biologics: a Canadian biotech innovator in therapeutic antibodies—new Jones Trading buy, $1B cap, cutting‑edge tech, promising growth in drug discovery.

AbCellera Biologics Inc. transforms antibody research into next‑generation therapies—discover its stock trends, valuation nuances, and biotech impact.

AbCellera Biologics Inc. faces significant financial challenges despite its innovative approach to therapeutic antibodies, raising questions about its sustainability and future prospects.

AbCellera Biologics Inc. has initiated a phase 1 trial for a novel menopause treatment, marking a significant step in the company’s mission to develop next-generation therapeutic antibodies.

AbCellera Biologics Inc. is a pioneering pharmaceutical company that is revolutionizing the healthcare sector through the discovery and development of next-generation therapeutic antibodies.

AbCellera Biologics Inc. is a Canadian pharmaceutical company that uses advanced technologies to discover and develop innovative therapeutic antibodies.

AbCellera Biologics Inc. continues to innovate in the biotech sector, leveraging advanced technologies to develop next-generation therapeutic antibodies despite facing financial challenges in Q1 2025.